Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making ...

The FMS-like tyrosine kinase-3 (FLT3) gene is the most commonly mutated gene in acute myeloid leukemia (AML), and patients carrying internal tandem duplication (ITD) mutations have a poor prognosis.

Hairy-cell leukemia, a rare B-cell cancer driven by a BRAF mutation and manifesting with cytopenias and splenomegaly, is responsive to purine analogue chemotherapy and to BRAF inhibitors combined w ...

To determine the transforming properties of the kinase fusions, we assessed their ability to induce cytokine-independent proliferation in mouse interleukin-3–dependent Ba/F3 cells and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

In accordance with these new discoveries in mice, Rbm25 activity is also negatively correlated with white blood cell counts that mark poor survival in human patients with myeloid leukemia.

Study suggests sequential treatment with LSD1 inhibitors, followed by MEK kinase inhibitors offers a new potential strategy for treating AML genprowebdirectory Facebook Linkedin RSS Twitter Youtube ...

The panel of experts provide their closing thoughts on the burden of disease in leukemia and lymphoma and the Bruton tyrosine kinase inhibitor landscape. 2 Commerce Drive Suite 100 Cranbury, NJ ...

PurposeStereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for brain metastases in ...

“This was seen despite the high proportion of patients in the placebo group that went on to receive another third generation [tyrosine kinase inhibitor], specifically [Tagrisso], nearly 80%.” “And we ...

Management of Brain Metastases in Tyrosine Kinase Inhibitor–Naïve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis Authors : William J.